lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma

References

• Chedid MF, Kruel CRP, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig. 2017;30(4):272–278. doi:10.1590/0102-672020170004001129340553
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6(6):387–396. doi:10.21037/hbsn.2017.11.0129312973
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Cao D, Cai C, Ye M, et al. Differential metabonomic profiles of primary hepatocellular carcinoma tumors from alcoholic liver disease, HBV-infected, and HCV-infected cirrhotic patients. Oncotarget. 2017;8(32):53313–53325. doi:10.18632/oncotarget.1839728881813
   PubMedGoogle Scholar
• Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122(6):1609–1619.12016426
   PubMed Web of Science ®Google Scholar
• Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 2006;60(2):89–98. doi:10.1016/j.critrevonc.2006.06.00116860993
   PubMed Web of Science ®Google Scholar
• Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57(2):610–624. doi:10.1002/hep.2602922911555
   PubMed Web of Science ®Google Scholar
• Rapisarda V, Loreto C, Malaguarnera M, et al. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol. 2016;8(13):573–590. doi:10.4254/wjh.v8.i13.57327168870
   PubMedGoogle Scholar
• Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biology. 2012;9(6):703–719. doi:10.4161/rna.2048122664915
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159. doi:10.1038/nrg252119188922
   PubMed Web of Science ®Google Scholar
• Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–1189. doi:10.1158/0008-5472.CAN-12-285023243023
   PubMed Web of Science ®Google Scholar
• Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009;28(2):195–208. doi:10.1038/onc.2008.37318836484
   PubMed Web of Science ®Google Scholar
• Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6(12):1984–1992. doi:10.1097/JTO.0b013e3182307eac22088988
   PubMed Web of Science ®Google Scholar
• Qiu L, Tang Q, Li G, Chen K. Long non-coding RNAs as biomarkers and therapeutic targets: recent insights into hepatocellular carcinoma. Life Sci. 2017;191:273–282. doi:10.1016/j.lfs.2017.10.00728987633
   PubMed Web of Science ®Google Scholar
• Mehra M, Chauhan R. Long noncoding RNAs as a key player in hepatocellular carcinoma. Biomark Cancer. 2017;9:1179299x17737301. doi:10.1177/1179299X17737301
   PubMedGoogle Scholar
• Yao J, Chen Y, Wang Y, et al. Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas. Int J Clin Exp Pathol. 2014;7(6):2758–2767.25031695
   PubMed Web of Science ®Google Scholar
• Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Science. 2005;96(9):543–552. doi:10.1111/j.1349-7006.2005.00089.x16128739
   PubMed Web of Science ®Google Scholar
• Cheng Z, Li X, Ding J. Characteristics of liver cancer stem cells and clinical correlations. Cancer Lett. 2016;379(2):230–238. doi:10.1016/j.canlet.2015.07.04126272183
   PubMed Web of Science ®Google Scholar
• Fu X, Zhu X, Qin F, et al. Linc00210 drives Wnt/beta-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 2018;17(1):73. doi:10.1186/s12943-018-0783-329540185
   PubMedGoogle Scholar
• Yang B, Li M, Tang W, et al. Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun. 2018;9(1):678. doi:10.1038/s41467-018-03024-229445139
   PubMedGoogle Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):0–641. doi:10.1016/j.cell.2009.02.006
   Web of Science ®Google Scholar
• Guerrieri F. Long non-coding RNAs era in liver cancer. World Journal of Hepatology. 2015;7(16):1971–1973. doi:10.4254/wjh.v7.i16.197126261686
   PubMedGoogle Scholar
• Xiao ZD, Han L, Lee H, et al. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nature Communications. 2017;8(1):783. doi:10.1038/s41467-017-00902-z
   PubMedGoogle Scholar
• Zhan Y, Li Y, Guan B, et al. Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. Oncotarget. 2017;8(44):76656–76665. doi:10.18632/oncotarget.2079529100339
   PubMedGoogle Scholar
• Jin L, He Y, Tang S, Huang S. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. J Cell Physiol. 2018;233(6):4726–4734. doi:10.1002/jcp.2625729139562
   PubMed Web of Science ®Google Scholar
• Lu YB, Jiang Q, Yang MY, Zhou JX, Zhang Q. Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis. Oncotarget. 2017;8(51):88804–88814. doi:10.18632/oncotarget.2132129179477
   PubMedGoogle Scholar
• Yu J, Wang X, Lu Q, et al. Extracellular 5‘-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway. Int J Cancer. 2018;142(5):959–967. doi:10.1002/ijc.3111229047106
   PubMed Web of Science ®Google Scholar
• Wang J, Li XM, Bai Z, Chi BX, Wei Y, Chen X. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/GSK3beta/cyclin D1 pathway. J Ethnopharmacol. 2018;210:1–9. doi:10.1016/j.jep.2017.06.03728684297
   PubMed Web of Science ®Google Scholar
• Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590–603. doi:10.1038/sj.leu.240282412646949
   PubMed Web of Science ®Google Scholar
• Lee SH, Pyo CW, Hahm DH, Kim J, Choi SY. Iron-saturated lactoferrin stimulates cell cycle progression through PI3K/Akt pathway. Mol Cells. 2009;28(1):37–42. doi:10.1007/s10059-009-0102-319533041
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu S, Zhang S, et al. Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol Cells. 2011;31(3):225–230. doi:10.1007/s10059-011-0023-921350939
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao N, He H, Huang C, Luo J, Shi X. Vanadate activated Akt and promoted S phase entry. Mol Cell Biochem. 2004;255(1–2):227–237.14971663
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhao F, Zhu D, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3beta signaling pathway. Cell Physiol Biochem. 2018;48(3):891–904. doi:10.1159/00049195730032137
   PubMedGoogle Scholar
• Liu Y, Huang Y, Zhang J, et al. TIMMDC1 knockdown inhibits growth and metastasis of gastric cancer cells through metabolic inhibition and AKT/GSK3beta/beta-catenin signaling pathway. Int J Biol Sci. 2018;14(10):1256–1267. doi:10.7150/ijbs.2710030123074
   PubMed Web of Science ®Google Scholar
• Li J, Gong X, Jiang R, et al. Fisetin inhibited growth and metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via PTEN/Akt/GSK3beta signal pathway. Front Pharmacol. 2018;9:772. doi:10.3389/fphar.2018.0077230108501
   PubMed Web of Science ®Google Scholar
• Zhou F, Xue M, Qin D, et al. HIV-1 Tat promotes Kaposi‘s sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3beta signaling pathway. PLoS One. 2013;8(1):e53145. doi:10.1371/journal.pone.005314523301033
   PubMed Web of Science ®Google Scholar
• Kartha RV, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Frontiers in Genetics. 2014;5:8.24523727
   PubMed Web of Science ®Google Scholar
• Jiao C, Song Z, Chen J, et al. lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncology Reports. 2016;36(5):2960–2966. doi:10.3892/or.2016.512127667646
   PubMed Web of Science ®Google Scholar
• Xiao Y, Jiao C, Lin Y, et al. lncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells. DNA and Cell Biology. 2017;36(1):18–25. doi:10.1089/dna.2016.353327854515
   PubMed Web of Science ®Google Scholar
• Lv J, Fan HX, Zhao XP, et al. Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. Cancer Lett. 2016;382(2):166–175. doi:10.1016/j.canlet.2016.08.02927597739
   PubMed Web of Science ®Google Scholar
• Zhang K, Li Q, Kang X, Wang Y, Wang S. Identification and functional characterization of lncRNAs acting as ceRNA involved in the malignant progression of glioblastoma multiforme. Oncology Reports. 2016;36(5):2911–2925. doi:10.3892/or.2016.507027600337
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang Y, Qu D, Jiang T, Li S. Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J Exp Clin Cancer Res. 2011;30:33. doi:10.1186/1756-9966-30-2421447176
   PubMed Web of Science ®Google Scholar
• Chen J, Zeng J, Xin M, Huang W, Chen X. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res. 2011;43(10):681–686. doi:10.1055/s-0031-128630621932171
   PubMed Web of Science ®Google Scholar
• Zhong G, Li H, Shan T, Zhang N. CSN5 silencing inhibits invasion and arrests cell cycle progression in human colorectal cancer SW480 and LS174T cells in vitro. Int J Clin Exp Pathol. 2015;8(3):2809–2815.26045788
   PubMed Web of Science ®Google Scholar
• Zhang HS, Cao EH, Qin JF. Homocysteine induces cell cycle G1 arrest in endothelial cells through the PI3K/Akt/FOXO signaling pathway. Pharmacology. 2005;74(2):57–64. doi:10.1159/00008368415677884
   PubMed Web of Science ®Google Scholar
• Afshari CA, Barrett JC. Cell cycle controls: potential targets for chemical carcinogens? Environ Health Perspect. 1993;101(Suppl 5):9–14. doi:10.1289/ehp.93101s598013430
   PubMedGoogle Scholar
• Wu CD, Chou HW, Kuo YS, et al. Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy. Oncol Rep. 2012;27(1):94–100. doi:10.3892/or.2011.147621956494
   PubMed Web of Science ®Google Scholar
• Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306. doi:10.1038/nature0309415549091
   PubMed Web of Science ®Google Scholar
• Bonelli P, Tuccillo FM, Borrelli A, Schiattarella A, Buonaguro FM. CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int. 2014;2014:361020. doi:10.1155/2014/36102024605326
   PubMed Web of Science ®Google Scholar
• Orlando S, Gallastegui E, Besson A, et al. p27Kip1and p21Cip1collaborate in the regulation of transcription by recruiting cyclin–cdk complexes on the promoters of target genes. Nucleic Acids Research. 2015;43(14):6860–6873. doi:10.1093/nar/gkv59326071952
   PubMed Web of Science ®Google Scholar
• Guangan H, Zahid H, Huang Z, et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 2005;24:2929–2943. doi:10.1038/sj.onc.120847415735718
   PubMed Web of Science ®Google Scholar
• Charles JS. G1 phase progression: cycling on cue. Cell. 1994;79:551–555.7954821
   PubMed Web of Science ®Google Scholar
• Gu X, Xu ZY, Zhu LY, Wang LF, Li K, Pei Q. Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression. Onco Targets Ther. 2013;6:199–209. doi:10.2147/OTT.S3740723569384
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–707. doi:10.1038/366704a08259215
   PubMed Web of Science ®Google Scholar
• Liao K, Li J, Wang Z. Dihydroartemisinin inhibits cell proliferation via AKT/GSK3beta/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. Int J Clin Exp Pathol. 2014;7(12):8684–8691.25674233
   PubMed Web of Science ®Google Scholar